Gan & Lee Pharmaceuticals Co Ltd (603087) — Cash Flow-to-Debt Ratio
Gan & Lee Pharmaceuticals Co Ltd (603087) has a Cash Flow-to-Debt Ratio of 0.30x as of September 2025, meaning its operating cash flow of CN¥257.27 Million could theoretically repay 0% of its total liabilities (CN¥860.37 Million) in one year. See 603087 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Gan & Lee Pharmaceuticals Co Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Gan & Lee Pharmaceuticals Co Ltd across 13 annual periods. Also explore 603087 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Gan & Lee Pharmaceuticals Co Ltd (2013–2025)
Year-by-year debt coverage analysis for Gan & Lee Pharmaceuticals Co Ltd. For market capitalisation and broader financial context, see market cap of Gan & Lee Pharmaceuticals Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.79x | CN¥784.28 Million | CN¥998.57 Million | ▲ +44.5% |
| 2024 | 0.54x | CN¥537.31 Million | CN¥988.45 Million | ▲ +23.6% |
| 2023 | 0.44x | CN¥427.69 Million | CN¥972.52 Million | ▲ +51.4% |
| 2022 | 0.29x | CN¥296.68 Million | CN¥1.02 Billion | ▼ -81.5% |
| 2021 | 1.57x | CN¥1.08 Billion | CN¥686.02 Million | ▼ -27.9% |
| 2020 | 2.18x | CN¥1.24 Billion | CN¥569.09 Million | ▲ +5.1% |
| 2019 | 2.08x | CN¥1.15 Billion | CN¥555.88 Million | ▲ +110.6% |
| 2018 | 0.99x | CN¥418.04 Million | CN¥424.18 Million | ▼ -57.7% |
| 2017 | 2.33x | CN¥949.60 Million | CN¥408.00 Million | ▲ +5.3% |
| 2016 | 2.21x | CN¥769.63 Million | CN¥348.06 Million | ▲ +60.8% |
| 2015 | 1.37x | CN¥447.42 Million | CN¥325.41 Million | ▼ -26.0% |
| 2014 | 1.86x | CN¥305.22 Million | CN¥164.18 Million | ▼ -9.8% |
| 2013 | 2.06x | CN¥204.73 Million | CN¥99.33 Million | — |